Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent research, a team led by Dr. Armin Rehm presents an improved immunotherapy that ...
A research team at the Helmholtz-Zentrum Dresden-Rossendorf (HZDR) has developed a radiopharmaceutical molecule marker that ...
Cannabidiol (CBD), a non-intoxicating compound in marijuana, “holds substantial promise as an anti-tumor agent” in addition to its other anti-inflammatory properties, a new scientific review ...
The gut microbiome has been shown to influence tumor growth and contribute to therapeutic resistance. Scientists have ...
Morning Overview on MSN
Brain scans may soon match depression patients to the right treatment
For decades, treating major depression has involved a frustrating cycle of trial and error, with patients cycling through ...
The Duxbury mother accused of killing her three young children appeared for a hearing on Tuesday. A Springfield man is dead ...
Marker Therapeutics (MRKR) is a clinical-stage immuno-oncology Company with the worldwide exclusive license of Multi-Antigen Targeted T cells, a ...
Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with ...
Cancer is no longer considered untreatable, yet improving the accuracy and timeliness of diagnostics and treatment remains ...
Here are the top 5 soft tissue sarcoma articles of 2025: ...
Engineered CD4 T cells, once thought to be sidekicks, are now showing lethal promise against cancer. Their ability to target a common tumor marker could revolutionize treatment for many. Credit: Stock ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback